newsfilter
← Latest News
ACCESS Newswire·

Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)

BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for